Edition:
India

Qiagen NV (QGEN.N)

QGEN.N on New York Stock Exchange

49.81USD
1:30am IST
Change (% chg)

$-0.67 (-1.33%)
Prev Close
$50.48
Open
$50.00
Day's High
$50.00
Day's Low
$49.46
Volume
113,721
Avg. Vol
244,901
52-wk High
$55.26
52-wk Low
$27.99

Latest Key Developments (Source: Significant Developments)

Qiagen Q3 Preliminary Adj. EPS Of Around $0.58 CER
Tuesday, 13 Oct 2020 

Oct 13 (Reuters) - QIAGEN NV ::PRELIMINARY ADJUSTED EPS RESULTS FOR Q3 OF 2020 ARE FOR APPROXIMATELY $0.58 CER - A 61% INCREASE FROM ADJUSTED EPS OF $0.36 IN Q3 OF 2019.Q3 NET SALES GREW 26% AT ACTUAL RATES, AND ALSO ROSE 26% AT CONSTANT EXCHANGE RATES (CER), TO $481.3 MILLION FROM $382.7 MILLION IN SAME PERIOD OF 2019.EXPECTS CURRENCY MOVEMENTS AGAINST U.S. DOLLAR (REPORTING CURRENCY) TO HAVE A POSITIVE IMPACT ON RESULTS FOR Q3 OF 2020 OF LESS THAN ONE PERCENTAGE POINT ON NET SALES AT ACTUAL RATES AND LESS THAN $0.01 ON ADJUSTED EPS.  Full Article

Qiagen Acquires Remaining Stake In Neumodx Molecular For $248 Mln
Friday, 18 Sep 2020 

Sept 17 (Reuters) - Qiagen NV ::QIAGEN SAYS IT ACQUIRES REMAINING 80.1% STAKE IN DIAGNOSTICS INSTRUMENTS CO NEUMODX MOLECULAR FOR $248 MILLION IN CASH.QIAGEN SAYS NEUMODX MOLECULAR TRANSACTION WAS COMPLETED AFTER CO RECEIVED U.S. REGULATORY CLEARANCE FOR FULL ACQUISITION.  Full Article

Bio-Techne And Qiagen Announce Expansion And Extension Of Exosome Partnership
Thursday, 17 Sep 2020 

Sept 17 (Reuters) - BIO-TECHNE CORP ::BIO-TECHNE AND QIAGEN ANNOUNCE EXPANSION AND EXTENSION OF EXOSOME PARTNERSHIP.AGREEMENT GRANTS QIAGEN A NON-EXCLUSIVE DEVELOPMENT LICENSE TO BIO-TECHNE'S EXOSOME TECHNOLOGY FOR DEVELOPMENT OF COMPANION IN VITRO DIAGNOSTIC PRODUCTS (CDX-IVD) FOR EXISTING AND POTENTIAL BIOPHARMA PARTNERS.INITIAL PHASE OF CO-MARKETING AGREEMENT LASTS 24 MONTHS, WITH POTENTIAL TO EXTEND LONGER UPON FULFILLMENT OF CERTAIN CONDITIONS.EXTENDED COLLABORATION AND JOINT PRODUCT DEVELOPMENT AGREEMENT ENDS IN 2028 AND CAN BE EXTENDED IF MUTUALLY AGREED TO BY BOTH COMPANIES.  Full Article

Qiagen Appoints Lawrence A. Rosen As New Chairman
Friday, 21 Aug 2020 

Aug 21 (Reuters) - QIAGEN NV ::RESIGNATION OF CHAIRMAN OF THE SUPERVISORY BOARD.DR. HÅKAN BJÖRKLUND, CHAIRMAN OF SUPERVISORY BOARD, HAS RESIGNED FROM OFFICE AS CHAIRMAN OF SUPERVISORY BOARD WITH IMMEDIATE EFFECT AND HAS LEFT SUPERVISORY BOARD.LAWRENCE A. ROSEN HAS BEEN ELECTED BY SUPERVISORY BOARD AS NEW CHAIRMAN OF SUPERVISORY BOARD.  Full Article

Qiagen To Move Forward With Its Plans To Fully Buy Neumodx
Thursday, 13 Aug 2020 

Aug 13 (Reuters) - QIAGEN NV ::QIAGEN TO CONTINUE SUCCESSFUL GROWTH STRATEGY FOCUSED ON EXECUTION AND GREATER VALUE CREATION AFTER VOLUNTARY PUBLIC TAKEOVER OFFER FALLS SHORT.TENDER OFFER ACCEPTANCE OF 47% DID NOT REACH MINIMUM THRESHOLD OF 66.67%.QIAGEN SUPERVISORY BOARD AND MANAGING BOARD RESPECT VIEWS OF SHAREHOLDERS.FOCUS ON EXECUTION WITH STRONG OUTLOOK FOR 2020 AND 2021, QIAGEN TO CONTINUE STRATEGY OF CREATING VALUE THROUGH SAMPLE TO INSIGHT PORTFOLIO FOR GROWING MOLECULAR TESTING NEEDS.QIAGEN TO MOVE FORWARD WITH FULL ACQUISITION OF NEUMODX, ADDING VERSATILE INTEGRATED MOLECULAR TESTING PLATFORMS TO PORTFOLIO AND GAINING ACCESS TO U.S. AND OTHER MARKETS.ONGOING COMMITMENT TO SUPPORT GLOBAL RESPONSE TO CORONAVIRUS PANDEMIC.WE RESPECT DECISION OF OUR SHAREHOLDERS AND WILL NOW CONTINUE TO EXECUTE OUR STRATEGY.AS WE FOCUS ON GREATER VALUE CREATION, QIAGEN BUILDS ON A DISCIPLINED CAPITAL ALLOCATION POLICY ANCHORED BY A HEALTHY BALANCE SHEET TO SUPPORT INVESTMENTS INTO OUR BUSINESS ALONG WITH A COMMITMENT TO INCREASING RETURNS TO SHAREHOLDERS.QIAGEN'S BUSINESS PROSPECTS HAVE IMPROVED SIGNIFICANTLY, AS SHOWN IN OUR PERFORMANCE FOR FIRST HALF OF 2020 AND STRONG OUTLOOK FOR REST OF THIS YEAR AND FOR 2021.WE WILL ALSO MOVE FORWARD WITH OUR PLANS TO FULLY ACQUIRE NEUMODX, INC..  Full Article

Thermo Fisher Scientific Says Has Terminated Acquisition Agreement With Qiagen
Thursday, 13 Aug 2020 

Aug 13 (Reuters) - Thermo Fisher Scientific Inc ::THERMO FISHER SCIENTIFIC ANNOUNCES RESULTS OF OFFER TO ACQUIRE QIAGEN, LAPSE OF OFFER AND TERMINATION OF ACQUISITION AGREEMENT.THERMO FISHER SCIENTIFIC INC - HAS TERMINATED ACQUISITION AGREEMENT WITH QIAGEN.THERMO FISHER SCIENTIFIC INC - QIAGEN WILL PAY TO THERMO FISHER AN EXPENSE REIMBURSEMENT PAYMENT OF USD 95 MILLION IN CASH.  Full Article

Qiagen Publishes Position Statement For Proposed Acquisition By Thermo Fisher
Wednesday, 22 Jul 2020 

July 22 (Reuters) - QIAGEN NV ::QIAGEN ANNOUNCES PUBLICATION OF SUPPLEMENTAL REASONED POSITION STATEMENT FOR PROPOSED ACQUISITION BY THERMO FISHER.QIAGEN NV - OFFER DOCUMENT RELATES TO RECOMMENDED OFFER BY THERMO FISHER TO FULLY ACQUIRE ALL ISSUED ORDINARY SHARES IN QIAGEN FOR AN INCREASED OFFER PRICE OF EUR 43.00 PER QIAGEN SHARE IN CASH, AS ANNOUNCED ON JULY 16, 2020..  Full Article

Davidson Kempner Says It Is Increasingly Apparent That Fair Value Of Qiagen Is Well In Excess Of Current Stock Price
Wednesday, 15 Jul 2020 

July 15 (Reuters) - Davidson Kempner says::SIGNIFICANT PROFIT UPGRADE CONFIRMS CONCERNS THAT QIAGEN IS SEVERELY UNDERVALUED BY CURRENT THERMO FISHER SCIENTIFIC OFFER.IT IS INCREASINGLY APPARENT THAT FAIR VALUE OF QIAGEN IS WELL IN EXCESS OF CURRENT STOCK PRICE.USING COMPANY'S OWN UPDATED NUMBERS OF $2/SHARE OF ADJUSTED EPS FOR 2020 RESULTS IN A VALUATION OF EUR 51.3/SHARE, ON $2.36/SHARE OF ADJUSTED EPS FOR 2021 RESULTS IN A VALUATION OF EUR 55.7/SHARE.  Full Article

Qiagen Q2 Net Sales Rose About 18-19% Compared To Year Ago
Thursday, 9 Jul 2020 

July 9 (Reuters) - QIAGEN NV ::Q2 NET SALES ROSE APPROXIMATELY 18-19% AT CONSTANT EXCHANGE RATES (CER) FROM $381.6 MILLION IN SAME PERIOD OF 2019.BETTER-THAN-EXPECTED NET SALES GROWTH REFLECTS VERY SIGNIFICANT DEMAND FOR SOLUTIONS USED IN COVID-19 PANDEMIC TESTING AGAINST WEAKER CUSTOMER DEMAND TRENDS IN OTHER PRODUCT AREAS.CONTINUES TO EXPERIENCE UNPRECEDENTED DEMAND FOR PRODUCTS USED IN CORONAVIRUS TESTING.EXPECTS CURRENCY MOVEMENTS AGAINST U.S. DOLLAR (REPORTING CURRENCY) TO HAVE AN ADVERSE IMPACT ON RESULTS FOR Q2 OF 2020 OF ABOUT 2-3 PERCENTAGE POINTS ON NET SALES AT ACTUAL RATES.  Full Article

Thermo Fisher Scientific Publishes Offer Document For Voluntary Tender Offer For All Ordinary Shares Of Qiagen N.V.
Monday, 18 May 2020 

May 18 (Reuters) - Thermo Fisher Scientific ::THERMO FISHER SCIENTIFIC PUBLISHES OFFER DOCUMENT FOR VOLUNTARY TENDER OFFER FOR ALL ORDINARY SHARES OF QIAGEN N.V..THERMO FISHER SCIENTIFIC INC - TRANSACTION EXPECTED TO CLOSE IN FIRST HALF OF 2021.THERMO FISHER SCIENTIFIC INC - ACCEPTANCE PERIOD FOR CASH OFFER OF EUR 39 PER QIAGEN SHARE RUNS FROM MAY 18, 2020, TO JULY 27, 2020.  Full Article

Photo

Qiagen readies launch of rapid COVID-19 antigen test

German diagnostic test maker Qiagen on Tuesday said it planned to launch a COVID-19 antigen test that can provide results in 15 minutes and test about 30 samples in an hour.